nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Correction to: Expression of Concern: Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancer
|
Lin, Zhifeng |
|
2019 |
36 |
6 |
p. 1 |
artikel |
2 |
Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21
|
Liang, Zumu |
|
2019 |
36 |
6 |
p. 1-10 |
artikel |
3 |
Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma
|
Kobayashi, Takahiro |
|
2019 |
36 |
6 |
p. 1-7 |
artikel |
4 |
Intra- and inter-observer variability in breast tumour bed contouring and the controversial role of surgical clips
|
Corrao, Giulia |
|
2019 |
36 |
6 |
p. 1-8 |
artikel |
5 |
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
|
Nagata, Naoki |
|
2019 |
36 |
6 |
p. 1-12 |
artikel |
6 |
N-Glycosylation in progression of skin cancer
|
Tang, Ling |
|
2019 |
36 |
6 |
p. 1-10 |
artikel |
7 |
Performance of a new system using a one-step nucleic acid amplification assay for detecting lymph node metastases in breast cancer
|
Shimazu, Kenzo |
|
2019 |
36 |
6 |
p. 1-8 |
artikel |
8 |
Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction
|
De Rose, Fiorenza |
|
2019 |
36 |
6 |
p. 1-8 |
artikel |
9 |
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
|
Tanaka, Hisashi |
|
2019 |
36 |
6 |
p. 1-8 |
artikel |
10 |
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)
|
Hidaka, Hisashi |
|
2019 |
36 |
6 |
p. 1-11 |
artikel |
11 |
Timing of treatment in small-cell lung cancer
|
Bhandari, Shruti |
|
2019 |
36 |
6 |
p. 1-5 |
artikel |
12 |
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease
|
Shibaki, Ryota |
|
2019 |
36 |
6 |
p. 1-8 |
artikel |